

CIMETRIL®
Brand of Cimetidine, USP
Anti-Ulcer

DESCRIPTION:

CIMETRIL®, brand of Cimetidine, is a histamine H₂ receptor antagonist.

PROPERTIES:

CIMETRIL® is a H₂ receptor antagonist. It reversibly compete with histamine at H₂ receptor sites. The most important actions of cimetidine is to reduce the secretion of gastric acid. **CIMETRIL®** can bind to androgen receptors.

PHARMACOKINETICS:

CIMETRIL® is well absorbed following oral administration, and peak plasma levels are observed 1 - 2 hours following each dose. The half-life of cimetidine is approximately 2 hours. It is widely distributed, crosses the placenta, and has been detected in breast milk. **CIMETRIL®** is excreted in the urine mostly unchanged.

INDICATIONS:

CIMETRIL® is indicated in the treatment of active duodenal ulcer, prophylaxis of recurrent ulcer, reflux oesophagitis and pathological hypersecretory conditions such as Zollinger - Ellison syndrome.

CONTRAINDICATIONS:

None known.

PRECAUTIONS:

CIMETRIL® may mask symptoms and delay diagnosis of gastric malignancies. Should exclude the possibility of malignancy prior to therapy. In patients with impaired renal function, the dose should be reduced.

ADVERSE REACTIONS:

Diarrhea, muscle pain, dizziness and skin rashes may occasionally occur. Reversible confusional states may also occur especially in the elderly or debilitated patients. Other side effects reported include allergy, enlargement of the breast, fever, acute pancreatitis, cardiac arrhythmia and loss of libido.

DOSAGE & ADMINISTRATION:

Indications	Oral Dose Adults
- Active duodenal ulcer	200 mg 3 times a day with meals and 400 mg at bedtime for at least 4 weeks
- Benign gastric ulcer	200 mg 3 times a day and 400 mg at bedtime for at least 6 weeks.
- Prophylaxis of recurrent ulcer	400 mg at bedtime. Some patients may require 400 mg at bedtime and 400 mg in the morning, for at least 6 months.
- Pathological hypersecretory conditions (i.e. Zollinger - Ellison syndrome)	400 mg 4 times a day with meals and at bedtime for 4 - 8 weeks.
- Reflux oesophagitis	

DRUG INTERACTIONS:

CIMETRIL® significantly inhibits the P-450 oxidative drug metabolizing system. Thus it reduces the metabolism of warfarin type anticoagulants, phenytoin, propranolol, chlordiazepoxide, diazepam, theophylline, cyclosporin, nifedipine, and diltiazem.

AVAILABILITY:

Tablets : Packs of 24 tablets each containing Cimetidine 400 mg, Excipient q.s.
1 tablet.
Reg. No.:
Lebanon: 27524.

Packs of 32 tablets each containing Cimetidine 200 mg, Excipient q.s.
1 tablet.
Reg. No.:
Lebanon: 27525.